<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医麦客 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-15T12:12:28+08:00</updated>
  <subtitle>医麦客是一个聚焦转化医学、精准医疗和生物制药的专业媒体平台，持续关注体外诊断、抗体药物、细胞治疗、基因治疗等细分领域。为新生物医药医疗领域的企业发声，推动企业和行业的快速发展。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>重磅 |《治疗用生物制品病毒污染风险控制要点》正式发布</title>
    <updated>2021-01-14T19:10:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/UqWO3iQpL4VRgKEccQxZ5Q</id>
    <link href="https://mp.weixin.qq.com/s/UqWO3iQpL4VRgKEccQxZ5Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>LILRB2单抗治疗实体瘤进入1期临床，巨噬细胞靶向疗法热度不减丨医麦猛爆料</title>
    <updated>2021-01-14T19:10:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/FrU1kwzqDy3pCPf1AsXgpg</id>
    <link href="https://mp.weixin.qq.com/s/FrU1kwzqDy3pCPf1AsXgpg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复宏汉霖逾1亿美元布局TROP-2单抗丨医麦猛爆料</title>
    <updated>2021-01-14T19:10:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/MkqLzuZFCskLisG4v9Mhtg</id>
    <link href="https://mp.weixin.qq.com/s/MkqLzuZFCskLisG4v9Mhtg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>继与诺华达成22亿美元合作之后，百济神州PD-1再批新适应症丨医麦猛爆料</title>
    <updated>2021-01-14T19:10:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/dMVKSl3QwsFTVgnrBWSePQ</id>
    <link href="https://mp.weixin.qq.com/s/dMVKSl3QwsFTVgnrBWSePQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药融资丨永泰生物与T-Cure达成1200万美元的合作，推进TCR-T疗法</title>
    <updated>2021-01-14T19:10:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/OtloyTsTKvqTVjmd-toCMQ</id>
    <link href="https://mp.weixin.qq.com/s/OtloyTsTKvqTVjmd-toCMQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>亘喜生物GC007g国内首个供者来源异基因CAR-T细胞疗法获批进入I/II期注册临床研究</title>
    <updated>2021-01-14T00:08:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/hUegi9JCZZmhMFqmAw8Kng</id>
    <link href="https://mp.weixin.qq.com/s/hUegi9JCZZmhMFqmAw8Kng" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>假病毒是新冠检测及治疗的关键利器吗？丨医麦猛爆料</title>
    <updated>2021-01-14T00:08:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/LGxOb-Wy-1LbaZw9UTLVuQ</id>
    <link href="https://mp.weixin.qq.com/s/LGxOb-Wy-1LbaZw9UTLVuQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>治疗实体瘤！赛诺菲1.25亿美元下注ILT2单抗，ILT2会是下一个PD-1/L1吗？丨医麦猛爆料</title>
    <updated>2021-01-14T00:08:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/mrSC8_a4V0WCcgFlBP-3JQ</id>
    <link href="https://mp.weixin.qq.com/s/mrSC8_a4V0WCcgFlBP-3JQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复盘2020，各适应症的基因治疗研发进度动态（下）丨星耀研究院</title>
    <updated>2021-01-14T00:08:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/ZogEpVPO4c1l7hIWO95L8Q</id>
    <link href="https://mp.weixin.qq.com/s/ZogEpVPO4c1l7hIWO95L8Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2021China Focus全球生命科学线上峰会议程（1.12-14）</title>
    <updated>2021-01-14T00:08:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/82FLyHeDGMM4_Nxnpe209Q</id>
    <link href="https://mp.weixin.qq.com/s/82FLyHeDGMM4_Nxnpe209Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Nature两篇连发，创新型mRNA递送技术将引领基因治疗领域新一轮风潮丨医麦新观察</title>
    <updated>2021-01-12T23:42:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/DtFbWN7PSzWtsoDLpkvf6w</id>
    <link href="https://mp.weixin.qq.com/s/DtFbWN7PSzWtsoDLpkvf6w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>又一例脑白患儿重获新生，优卡迪ssCART-19治疗中枢神经系统浸润白血病安全有效丨医麦猛爆料</title>
    <updated>2021-01-12T23:42:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/SBtn25rGAtr8D2cYBQ7qJg</id>
    <link href="https://mp.weixin.qq.com/s/SBtn25rGAtr8D2cYBQ7qJg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复宏汉霖CD38单抗获批临床，CD38靶点成为治疗多发性骨髓瘤的热门靶点丨医麦猛爆料</title>
    <updated>2021-01-12T23:42:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/FBqnXdomuCX3722q1RIYYg</id>
    <link href="https://mp.weixin.qq.com/s/FBqnXdomuCX3722q1RIYYg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>EpCAM ADC临床试验申请获得国家药监局受理丨医麦猛爆料</title>
    <updated>2021-01-12T23:42:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/Dagk-7sUfk9QRIKjwoZyLA</id>
    <link href="https://mp.weixin.qq.com/s/Dagk-7sUfk9QRIKjwoZyLA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药融资丨罗氏看好的RNAi疗法获1.1亿美元启动</title>
    <updated>2021-01-12T23:42:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/RfgygIEOp5eUWRQt89TxAg</id>
    <link href="https://mp.weixin.qq.com/s/RfgygIEOp5eUWRQt89TxAg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药融资丨新锐公司获得3000万美元的融资，布局鸡尾酒疗法</title>
    <updated>2021-01-12T23:42:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/O4s77G1lhAOFDYefti1ZGw</id>
    <link href="https://mp.weixin.qq.com/s/O4s77G1lhAOFDYefti1ZGw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>单剂干细胞治疗成功降低心力衰竭患者的心脏病发作、中风和心源性死亡的风险丨医麦猛爆料</title>
    <updated>2021-01-12T08:09:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/JrNNIHtHEtx0DGdimLo0-Q</id>
    <link href="https://mp.weixin.qq.com/s/JrNNIHtHEtx0DGdimLo0-Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复盘2020，各适应症的基因治疗研发进度动态（上）丨星耀研究院</title>
    <updated>2021-01-12T08:09:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/fzS3hL_t95zqmjWkCrpPZg</id>
    <link href="https://mp.weixin.qq.com/s/fzS3hL_t95zqmjWkCrpPZg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内双特异性抗体药物临床申报持续火热丨医麦新观察</title>
    <updated>2021-01-12T08:09:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/NtEfbc9KlRwnve17TLvntQ</id>
    <link href="https://mp.weixin.qq.com/s/NtEfbc9KlRwnve17TLvntQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>重磅数据！BioMarin公布A型血友病基因疗法3期试验的一年随访数据丨医麦猛爆料</title>
    <updated>2021-01-12T08:09:07+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/ZKmMZfKwBufdFzeJtdeFug</id>
    <link href="https://mp.weixin.qq.com/s/ZKmMZfKwBufdFzeJtdeFug" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>